Analysis of Gene Expression in Early-Stage Ovarian Cancer
- 1 December 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (23) , 7850-7860
Abstract
Purpose: Advanced prostate cancer is first treated with androgen deprivation therapy. However, tumors become resistant to and grow despite castrate levels of testosterone. Growth and proliferation of CRPC is mediated by gain-of-function changes in the AR and AR reactivation. Expression of manganese superoxide dismutase (SOD2), which regulates cellular ROS, is markedly down-regulated in CRPC when compared with hormone-responsive tumors.Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancerEuropean Journal of Cancer, 2007
- ΔNp63 expression is associated with poor survival in ovarian cancerAnnals of Oncology, 2007
- Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implicationsBritish Journal of Cancer, 2007
- The Inflammatory Cytokine Tumor Necrosis Factor-α Generates an Autocrine Tumor-Promoting Network in Epithelial Ovarian Cancer CellsCancer Research, 2007
- Grb10 and Grb14: enigmatic regulators of insulin action – and more?Biochemical Journal, 2005
- Pairwise Interactions of the Six Human MCM Protein SubunitsJournal of Molecular Biology, 2004
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001
- Survival of European women with gynaecological tumours, during the period 1978–1989European Journal of Cancer, 1998
- Tumour necrosis factor and cancerProgress in Growth Factor Research, 1992
- Estimating the Error Rate of a Prediction Rule: Improvement on Cross-ValidationJournal of the American Statistical Association, 1983